Previous 10 | Next 10 |
- Data provide key insights supporting Edgewise’s strategy to advance EDG-5506 for the treatment of Duchenne and Becker muscular dystrophy - Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted...
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the virtual Stifel 2023 CNS Days...
– Podium presentation on March 22, 2023 – – Company to host an Industry Forum to discuss its new approach to protecting dystrophic muscle featuring a key opinion leader – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceu...
– President and Chief Medical Officer (CMO) of BridgeBio Pharma and Former CMO of MyoKardia brings strong cardiovascular expertise to Edgewise – Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavaila...
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the Cowen 43rd Annual Health Car...
– Presentation highlights EDG-7500, an investigational first-in-class oral, selective, sarcomere modulator for hypertrophic cardiomyopathy (HCM) on March 5, 2023 – Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developi...
Reata Pharmaceuticals ( NASDAQ: RETA ) lost ~32% on Monday to reach the lowest level in over four months as a key FDA official leaves the agency while the company awaits the U.S. approval for its Friedreich's ataxia ((F.A.)) therapy, omaveloxolone. Earlier in the day, multiple new...
Edgewise Therapeutics press release ( NASDAQ: EWTX ): Q4 GAAP EPS of -$0.31 beats by $0.05 . Cash, cash equivalents and marketable securities were $352 million as of December 31, 2022. For further details see: Edgewise Therapeutics GAAP EPS of -$0.31 beats by $0.05
– Advancing Phase 2 trials of EDG-5506 in Becker muscular dystrophy (BMD, CANYON ) and Duchenne muscular dystrophy (DMD, LYNX); Initiated Phase 2 exercise challenge trial of EDG-5506 in Limb girdle muscular dystrophy 2i (LGMD2I), BMD and McArdle’s Disease (DUNE) ...
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the virtual SVB Securities Globa...
News, Short Squeeze, Breakout and More Instantly...
Edgewise Therapeutics Inc. Company Name:
EWTX Stock Symbol:
NASDAQ Market:
Edgewise Therapeutics Inc. Website:
2024-07-01 09:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-30 19:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...